Combined phosphatase and tensin homolog (PTEN) loss and fatty acid synthase (FAS) overexpression worsens the prognosis of Chinese patients with hepatocellular carcinoma

International Journal of Molecular Sciences

Volumn 13, Issue 8, 2012, Pages 9980-9991

  Zhu, Xuehua ^a   Qin, Xia ^b,c   Fei, Maogui ^d   Hou, Wenmin ^d   Greshock, Joel ^c   Bachman, Kurtis E ^c   Wooster, Richard ^c   Kang, Jiuhong ^a   Qin, Crystal Ying ^b,c  

^a TONGJI UNIVERSITY   (China)

^b GLAXOSMITHKLINE   (China)

^c GLAXOSMITHKLINE   (United States)

^d Chinese Academy of Sciences   (China)

Author keywords

Chinese; FAS; Hepatocellular carcinoma; Prognosis; PTEN

Indexed keywords

FATTY ACID SYNTHASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TUMOR MARKER; FASN PROTEIN, HUMAN; PTEN PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CHINESE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DISEASE MARKER; DOWN REGULATION; FEMALE; GENE LOSS; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN LOCALIZATION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; CANCER STAGING; CHINA; ENZYME IMMUNOASSAY; GENE EXPRESSION REGULATION; LIVER TUMOR; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SECONDARY; SURVIVAL RATE; TUMOR INVASION;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; CHINA; FATTY ACID SYNTHASE, TYPE I; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROGNOSIS; PTEN PHOSPHOHYDROLASE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84865046779     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms13089980     Document Type: Article

References (25)

1. Okuda, K. Hepatocellular carcinoma. J. Hepatol. 2000, 32, 225-237.
2. Chen, C.J.; Yu, M.W.; Liaw, Y.F. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J. Gastroenterol. Hepatol. 1997, 12, S294-S308.
3. Sherman, M. Hepatocellular carcinoma: Epidemiology, risk factors, and screening. Semin. Liver Dis. 2005, 25, 143-154.
4. Li, J.; Yen, C.; Liaw, D.; Podsypanina, K.; Bose, S.; Wang, S.I.; Puc, J.; Miliaresis, C.; Rodgers, L.; McCombie, R., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275, 1943-1947.
5. Tamura, M.; Gu, J.; Tran, H.; Yamada, K.M. PTEN gene and integrin signaling in cancer. J. Natl. Cancer Inst. 1999, 91, 1820-1828.
6. Eng, C. PTEN: One gene, many syndromes. Hum. Mutat. 2003, 22, 183-198.
7. di Cristofano, A.; Pandolfi, P.P. The multiple roles of PTEN in tumor suppression. Cell 2000, 100, 387-390.
8. Hollander, M.C.; Blumenthal, G.M.; Dennis, P.A. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat. Rev. Cancer 2011, 11, 289-301.
9. Menendez, J.A.; Lupu, R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 2007, 7, 763-777.
10. van de Sande, T.; de Schrijver, E.; Heyns, W.; Verhoeven, G.; Swinnen, J.V. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Res. 2002, 62, 642-646.
11. Stiles, B.; Wang, Y.; Stahl, A.; Bassilian, S.; Lee, W.P.; Kim, Y.J.; Sherwin, R.; Devaskar, S.; Lesche, R.; Magnuson, M.A.; Wu, H. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc. Natl. Acad. Sci. USA 2004, 101, 2082-2087.
12. Remmele, W.; Stegner, H.E. Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 1987, 8, 138-140.
13. Salmena, L.; Carracedo, A.; Pandolfi, P.P. Tenets of PTEN tumor suppression. Cell 2008, 133, 403-414.
14. Manning, B.D.; Cantley, L.C. AKT/PKB signaling: Navigating downstream. Cell 2007, 129, 1261-1274.
15. Kim, D.; Kim, S.; Koh, H.; Yoon, S.O.; Chung, A.S.; Cho, K.S.; Chung, J. Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J. 2001, 15, 1953-1962.
16. Song, M.S.; Carracedo, A.; Salmena, L.; Song, S.J.; Egia, A.; Malumbres, M.; Pandolfi, P.P. Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner. Cell 2011, 144, 187-199.
17. Gimm, O.; Perren, A.; Weng, L.P.; Marsh, D.J.; Yeh, J.J.; Ziebold, U.; Gil, E.; Hinze, R.; Delbridge, L.; Lees, J.A., et al. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. Am. J. Pathol. 2000, 156, 1693-1700.
18. McMenamin, M.E.; Soung, P.; Perera, S.; Kaplan, I.; Loda, M.; Sellers, W.R. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 1999, 59, 4291-4296.
19. Halvorsen, O.J.; Haukaas, S.A.; Akslen, L.A. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin. Cancer Res. 2003, 9, 1474-1479.
20. Sze, K.M.; Wong, K.L.; Chu, G.K.; Lee, J.M.; Yau, T.O.; Ng, I.O. Loss of phosphatase and tensin homolog enhances cell invasion and migration through AKT/Sp-1 transcription factor/matrix metalloproteinase 2 activation in hepatocellular carcinoma and has clinicopathologic significance. Hepatology 2011, 53, 1558-1569.
21. Chen, J.S.; Wang, Q.; Fu, X.H.; Huang, X.H.; Chen, X.L.; Cao, L.Q.; Chen, L.Z.; Tan, H.X.; Li, W.; Bi, J., et al. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol. Res. 2009, 39, 177-186.
22. Hu, T.H.; Huang, C.C.; Lin, P.R.; Chang, H.W.; Ger, L.P.; Lin, Y.W.; Changchien, C.S.; Lee, C.M.; Tai, M.H. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer 2003, 97, 1929-1940.
23. Wu, S.K.; Wang, B.J.; Yang, Y.; Feng, X.H.; Zhao, X.P.; Yang, D.L. Expression of PTEN, PPM1A and P-Smad2 in hepatocellular carcinomas and adjacent liver tissues. World J. Gastroenterol. 2007, 13, 4554-4559.
24. Bandyopadhyay, S.; Pai, S.K.; Watabe, M.; Gross, S.C.; Hirota, S.; Hosobe, S.; Tsukada, T.; Miura, K.; Saito, K.; Markwell, S.J., et al. FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis. Oncogene 2005, 24, 5389-5395.
25. Hu, T.H.; Wang, C.C.; Huang, C.C.; Chen, C.L.; Hung, C.H.; Chen, C.H.; Wang, J.H.; Lu, S.N.; Lee, C.M.; Changchien, C.S., et al. Down-regulation of tumor suppressor gene PTEN, overexpression of p53, plus high proliferating cell nuclear antigen index predict poor patient outcome of hepatocellular carcinoma after resection. Oncol. Rep. 2007, 18, 1417-1426.